Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06277934 · ClinicalTrials.gov registry record · Phase 2
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
A Phase 2 study, sponsored by Regor Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT06277934: Completed Phase 2 study, sponsored by Regor Pharmaceuticals.
NCT06277934 is a Phase 2 study that has completed, run by Regor Pharmaceuticals. The registered enrollment target is 73 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06277934, a Phase 2 study, has completed, sponsored by Regor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
Interventions
- DRUG Placebo
- DRUG RGT001-075
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-03-08 |
| Est. Completion | 2024-08-13 |
| Phase | Phase 2 |
What the finished NCT06277934 record still lists
NCT06277934 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06277934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06277934 about?
NCT06277934 is a clinical study titled "A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities". The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
What is the current status of trial NCT06277934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2024-03-08. Estimated completion is 2024-08-13.
What interventions are being tested in trial NCT06277934?
The interventions under investigation include: Placebo (DRUG), RGT001-075 (DRUG).
Who is sponsoring clinical trial NCT06277934?
This trial is sponsored by Regor Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06277934's enrollment target sits among peer trials
73 924th of 2000 higher than 1,076 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI